Tesaro (TSRO) PT Raised to $120 at Baird
Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.
Baird analyst Michael Ulz reiterated an Outperform rating and raised his price target on Tesaro (NASDAQ: TSRO) to $120.00 (from $105.00) with full niraparib data better than expected.
Ulz commented, "Over the weekend, detailed data from the Phase 3 NOVA study of niraparib in 2L+ maintenance of ovarian cancer were presented at the ESMO meeting and published in the NEJM. Overall, the updated data further strengthens niraparib's market-leading position, supporting broad use across all platinum-sensitive patients with a manageable safety profile. Filing remains on track to complete in 4Q16, and we continue to anticipate approval in 1H17. We reiterate our Outperform rating and raise our price target to $120."
Shares of Tesaro closed at $99.26 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Wedbush Raises Price Target on Citizens Financial Group (CFG) Following 3Q EPS Beat
- UPDATE: Seaport Global Securities Starts Union Pacific (UNP) at Buy
- Piper Jaffray Cuts PT on Inovio Pharma (INO) to $13 Following FDA Clinical Hold; Affirms at 'Overweight'
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst PT Change
Related EntitiesRobert W Baird
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!